Information Provided By:
Fly News Breaks for April 25, 2016
JAZZ
Apr 25, 2016 | 06:35 EDT
SunTrust analyst John Boris upgraded Jazz Pharmaceuticals to Buy and increased his price target to $200 from $165 in anticipation of a Xyrem patent settlement in 2022E allowing for a gradual generic entry in 2022-2025, increased transparency on a Xyrem line extensions, execution on pipeline launches of Defitelio and JZP110, and potential acquisitions.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ